Europe South Asia Asia Pacific Americas Middle East Africa BBC Homepage World Service Education



Front Page

World

UK

UK Politics

Business

Sci/Tech

Health

Education

Sport

Entertainment

Talking Point

In Depth

On Air

Archive
Feedback
Low Graphics
Help

Thursday, September 2, 1999 Published at 07:31 GMT 08:31 UK


Health

Cost warning on flu drug

Demand on GPs for flu drugs could swamp the system

Government advisors are warning that a drug which helps flu sufferers could cost the NHS about £115m if there is an epidemic.


The BBC's Health Correspondent Richard Hannaford reports on the cost of a new anti-flu drug
The National Prescribing Centre has sent a bulletin to health service managers warning that the arrival of zanamivir or Relenza, which costs around £24 a dose, could "increase expectation dramatically".

Although doctors' organisations have already warned about the dangers posed by the drug, this is the first time the potential for chaos has been acknowledged by the NHS.

The document, obtained by Doctor newspaper, predicts that 4.8 million people could need the drug during an epidemic year.

Until now, there have been no prescription drugs which help ease the suffering of flu patients - but this does not stop them approaching GPs for help.

Ad campaign ineffective

The new NHS
During the last epidemic, in the winter of 1989/90, 600 people in every 100,000 went to see their doctor with flu, even though a massive advertising campaign told them not to bother.

The fear is that with the first ever treatment for flu available, many more people will demand it.

The NPC says that consultation rates of just 400 in every 100,000 people mean that GPs have to suspend nearly all their other routine work.

Practices, it adds, would "go into crisis mode".

"In the current format of primary care, it is difficult to see how it might cope with such demand at times of epidemic."

The NPC's role is to provide and help co-ordinate the provision of effective information on medicines and prescribing related issues mainly to Health Authorities and GPs.

The drug's makers, Glaxo Wellcome, said that the NPC estimates were over the top. It does not expect more than 500,000 people to receive the drug in an average year.

Relenza, now licenced for use in the UK, has been shown to cut the length of flu attacks by up to two days if taken promptly.

The drug has been referred by the government to the National Institute for Clinical Excellence, who will decide whether it is sufficiently effective to allow it to be freely available on the NHS. A decision is expected by November.





Advanced options | Search tips




Back to top | BBC News Home | BBC Homepage | ©


Health Contents

Background Briefings
Medical notes

Relevant Stories

06 Aug 99†|†Health
NHS rationing: The key areas

06 Aug 99†|†Health
NHS agenda for expensive drugs

02 Jul 99†|†Health
Doctors fear over flu drug

18 Feb 99†|†Medical notes
Flu: The facts

18 Jan 99†|†Health
Flu hype worsened NHS crisis

05 Jan 99†|†Health
Flu hospital uses lorry as mortuary

05 Jan 99†|†Health
Extra cash to fight flu crisis





Internet Links


Influenza information

National Prescribing Centre


The BBC is not responsible for the content of external internet sites.




In this section

Disability in depth

Spotlight: Bristol inquiry

Antibiotics: A fading wonder

Mental health: An overview

Alternative medicine: A growth industry

The meningitis files

Long-term care: A special report

Aids up close

From cradle to grave

NHS reforms: A guide

NHS Performance 1999

From Special Report
NHS in crisis: Special report

British Medical Association conference '99

Royal College of Nursing conference '99